Greenland vs Qatar: Tuberculosis patients living with HIV receiving antiretroviral therapy
Greenland
3 patients
in 2021
Qatar
3 patients
in 2021
Greenland rank
117th
Qatar rank
117th
Tuberculosis patients living with HIV receiving antiretroviral therapy over time
- Greenland
- Qatar
How they compare
Greenland currently reports 3 patients against 3 patients in Qatar, a difference of 0 patients.
The two have swapped places 4 times across 8 shared years of data; in 2008 it was Qatar ahead.
Greenland ranks 117th and Qatar ranks 117th of 183 countries.
Greenland has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Greenland | Qatar | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.5 patients | 0.5 patients | 0 patients | — |
| 2010s | 0.4 patients | 0.2 patients | 0.2 patients | Greenland |
| 2020s | 3 patients | 3 patients | 0 patients | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher tuberculosis patients living with hiv receiving antiretroviral therapy, Greenland or Qatar?
- Greenland, at 3 patients against 3 patients in Qatar as of 2021.
- What is the difference in tuberculosis patients living with hiv receiving antiretroviral therapy between Greenland and Qatar?
- 0 patients, with Greenland ahead.
- How many years of comparable data are there for Greenland and Qatar?
- 8 years are reported by both, from 2008 to 2021.
- How do Greenland and Qatar rank globally for tuberculosis patients living with hiv receiving antiretroviral therapy?
- Greenland ranks 117th and Qatar ranks 117th of 183 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026); Population based on various sources (2024) – with minor processing by Our World in Data, published as Tuberculosis patients living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of tuberculosis patients who are living with HIV and receiving antiretroviral therapy.